摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

{5-chloro-1-[3-(2,6-dichloropyridin-4-yl-methoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid | 947687-97-0

中文名称
——
中文别名
——
英文名称
{5-chloro-1-[3-(2,6-dichloropyridin-4-yl-methoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid
英文别名
2-[5-Chloro-1-[3-[(2,6-dichloropyridin-4-yl)methoxy]phenyl]indol-3-yl]-2-oxoacetic acid
{5-chloro-1-[3-(2,6-dichloropyridin-4-yl-methoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid化学式
CAS
947687-97-0
化学式
C22H13Cl3N2O4
mdl
——
分子量
475.715
InChiKey
ZDKOVUDCMVQJQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6
  • 重原子数:
    31
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    81.4
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
    申请人:Wyeth
    公开号:US20040138283A1
    公开(公告)日:2004-07-15
    Compounds of formula I are provided: 1 wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.
    提供了化学式I的化合物:1其中:R1、R2和R3如此定义,在此定义中,以及使用这些化合物作为纤溶酶原激活抑制剂(PAI-1)的抑制剂和作为治疗成分治疗由纤溶障碍引起的病症的药物组合物和方法,例如深静脉血栓、冠心病和肺纤维化。
  • Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
    申请人:Jennings Dalton Lee
    公开号:US20070259922A1
    公开(公告)日:2007-11-08
    Compounds of formula I are provided: wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.
    提供了I式化合物,其中:R1、R2和R3如本文所定义,以及使用该化合物作为纤溶酶原激活抑制剂(PAI-1)的抑制剂的药物组合物和方法,以及作为治疗纤溶障碍引起的疾病,例如深静脉血栓、冠心病和肺纤维化的治疗组合物。
  • ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
    申请人:Wyeth
    公开号:EP1569901A2
    公开(公告)日:2005-09-07
  • US7259182B2
    申请人:——
    公开号:US7259182B2
    公开(公告)日:2007-08-21
  • US7674818B2
    申请人:——
    公开号:US7674818B2
    公开(公告)日:2010-03-09
查看更多